 China Grand Pharma announced a 340 million agreement to develop and commercialize Telix Pharmas molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy company, raised 300 million in its Hong Kong IPO at a market capitalization of 1 billion. 